Recognition of distinct epitopes on the HLA-A2 antigen by cytotoxic T lymphocytes. 1986

J J van der Poel, and J Pool, and E Goulmy, and M J Giphart, and J J van Rood

Alloimmune CTLs specifically recognizing the HLA-A2.3 subtype could be made besides the previously described HLA-A2.1 and A2.2 subtype-specific CTLs. Examination of the fine specificity of 15 different CTLs directed against distinct HLA-A2 subtypes demonstrated further complexity of antigenic epitopes present on the A2 molecule. First, epitopes could be defined which are unique for the HLA-A2.1, A2.2, A2.3, and A2.4 subtypes. Second, epitopes could be defined which are shared between the HLA-A2.1, A2.2 and A2.4 subtypes, but which are not shared by the A2.3 subtype. Analysis of the reactivity patterns of CTLs directed against the HLA-A2.2 and A2.4 subtypes indicated that the observed cytotoxic response was dependent on the HLA type of the responder cell. Biochemical analysis demonstrated the existence of isoelectric point variation in A2 heavy chains which deviated from the expected pIs for the A2 subtypes as described previously. Individuals were identified who possessed A2 heavy chains typical for the A2.3 subtype antigen although the CTL analysis demonstrated the presence of an A2.1 subtype antigen.

UI MeSH Term Description Entries
D007518 Isoantibodies Antibodies from an individual that react with ISOANTIGENS of another individual of the same species. Alloantibodies
D007526 Isoelectric Point The pH in solutions of proteins and related compounds at which the dipolar ions are at a maximum. Isoelectric Points,Point, Isoelectric,Points, Isoelectric
D006680 HLA Antigens Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases. Human Leukocyte Antigen,Human Leukocyte Antigens,Leukocyte Antigens,HL-A Antigens,Antigen, Human Leukocyte,Antigens, HL-A,Antigens, HLA,Antigens, Human Leukocyte,Antigens, Leukocyte,HL A Antigens,Leukocyte Antigen, Human,Leukocyte Antigens, Human
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000939 Epitopes Sites on an antigen that interact with specific antibodies. Antigenic Determinant,Antigenic Determinants,Antigenic Specificity,Epitope,Determinant, Antigenic,Determinants, Antigenic,Specificity, Antigenic
D013602 T-Lymphocytes, Cytotoxic Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2. Cell-Mediated Lympholytic Cells,Cytotoxic T Cells,Cytotoxic T Lymphocyte,Cytotoxic T-Lymphocytes,TC1 Cell,TC1 Cells,TC2 Cell,TC2 Cells,Cell Mediated Lympholytic Cells,Cell, Cell-Mediated Lympholytic,Cell, TC1,Cell, TC2,Cell-Mediated Lympholytic Cell,Cytotoxic T Cell,Cytotoxic T Lymphocytes,Cytotoxic T-Lymphocyte,Lymphocyte, Cytotoxic T,Lympholytic Cell, Cell-Mediated,Lympholytic Cells, Cell-Mediated,T Cell, Cytotoxic,T Lymphocyte, Cytotoxic,T Lymphocytes, Cytotoxic,T-Lymphocyte, Cytotoxic
D015789 HLA-A2 Antigen A specific HLA-A surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-A*02 allele family. HLA Class I Histocompatibility Antigen, A-2 alpha Chain,HLA-A2,Antigen, HLA-A2,HLA A2 Antigen,HLA Class I Histocompatibility Antigen, A 2 alpha Chain

Related Publications

J J van der Poel, and J Pool, and E Goulmy, and M J Giphart, and J J van Rood
November 2004, Breast cancer research and treatment,
J J van der Poel, and J Pool, and E Goulmy, and M J Giphart, and J J van Rood
August 2001, World journal of gastroenterology,
J J van der Poel, and J Pool, and E Goulmy, and M J Giphart, and J J van Rood
March 1989, Journal of immunology (Baltimore, Md. : 1950),
J J van der Poel, and J Pool, and E Goulmy, and M J Giphart, and J J van Rood
December 1989, Journal of immunology (Baltimore, Md. : 1950),
J J van der Poel, and J Pool, and E Goulmy, and M J Giphart, and J J van Rood
March 1998, International journal of cancer,
J J van der Poel, and J Pool, and E Goulmy, and M J Giphart, and J J van Rood
November 1984, Science (New York, N.Y.),
J J van der Poel, and J Pool, and E Goulmy, and M J Giphart, and J J van Rood
August 1983, Proceedings of the National Academy of Sciences of the United States of America,
J J van der Poel, and J Pool, and E Goulmy, and M J Giphart, and J J van Rood
January 2018, Journal of immunology research,
J J van der Poel, and J Pool, and E Goulmy, and M J Giphart, and J J van Rood
January 1982, Immunogenetics,
J J van der Poel, and J Pool, and E Goulmy, and M J Giphart, and J J van Rood
December 1988, Proceedings of the National Academy of Sciences of the United States of America,
Copied contents to your clipboard!